Objectives: The aim of this study was to compare the efficacy of palmitoylethanolamide (PEA) and non-steroidal antinflammatory drugs (NSAID) in the treatment of pain caused by temporomandibular joint disorders (TMJD). PEA is an endogenous agent (fatty acid amide) and its mechanism is an autacoid local inflammation antagonism. It is a regulator of mast cells behavior in the control of both acute and chronic inflammatory disease. Materials and Methods: A blind randomized clinical trial has been conduced on 25 patients (17 female and 8 male) aged 24-54, selected in a group of 120 subjects referred to Dental Department of the University of Bologna. This group of patients affected by temporomandibular joint's (TMJ) osteoarthritis or synovitis pain (axis I RDC/TMD) was randomly divided in 2 groups. Group A (13 subjects) received PEA (Normast) 300 mg in the morning and 600 mg in the evening for 7 days and then 300 mg twice a day for other 7 days. Group B (12 subject) took ibuprofen 600 mg 3 times a day for 2 weeks. Every patient recorded the intensity of their spontaneous pain using Visual Analogue Scale (VAS) twice a day (in the morning and evening) noting data in a diary. Maximum mouth opening was recorded by a blind operator during the first visit and after 14 days. Results: Mann-Whitney test was used to compare the course of pain during treatment. Pain decrease after two weeks of treatment was significantly higher in group A (PEA) than in group B (NSAID) (p=0.0001); masticatory function improves more in group A than in Group B (p=0.0001). Conclusions: Our preliminary data suggest that PEA is an effective tool for treatment of TMJD, in patients with synovitis and osteoarthritis pain. It is a non-gastrolesive effective analgesic with a longer half-life than NSAID (12 versus 4 hours).
Palmitoylethanolamide Vs NSAID In The Treatment Of TMJD Pain / F. BORTOLOTTI; M. RUSSO; M.L. BARTOLUCCI; G. ALESSANDRI BONETTI; M.R. GATTO; I. MARINI. - In: JOURNAL OF DENTAL RESEARCH. - ISSN 0022-0345. - ELETTRONICO. - 89(Spec Iss B):(2010), pp. 2137-2137. (Intervento presentato al convegno IADR/AADR 88th General Session tenutosi a Barcelona, Spain nel 14-17 Luglio 2010).
Palmitoylethanolamide Vs NSAID In The Treatment Of TMJD Pain
M. L. BARTOLUCCI;ALESSANDRI BONETTI, GIULIO;GATTO, MARIA ROSARIA;MARINI, IDA
2010
Abstract
Objectives: The aim of this study was to compare the efficacy of palmitoylethanolamide (PEA) and non-steroidal antinflammatory drugs (NSAID) in the treatment of pain caused by temporomandibular joint disorders (TMJD). PEA is an endogenous agent (fatty acid amide) and its mechanism is an autacoid local inflammation antagonism. It is a regulator of mast cells behavior in the control of both acute and chronic inflammatory disease. Materials and Methods: A blind randomized clinical trial has been conduced on 25 patients (17 female and 8 male) aged 24-54, selected in a group of 120 subjects referred to Dental Department of the University of Bologna. This group of patients affected by temporomandibular joint's (TMJ) osteoarthritis or synovitis pain (axis I RDC/TMD) was randomly divided in 2 groups. Group A (13 subjects) received PEA (Normast) 300 mg in the morning and 600 mg in the evening for 7 days and then 300 mg twice a day for other 7 days. Group B (12 subject) took ibuprofen 600 mg 3 times a day for 2 weeks. Every patient recorded the intensity of their spontaneous pain using Visual Analogue Scale (VAS) twice a day (in the morning and evening) noting data in a diary. Maximum mouth opening was recorded by a blind operator during the first visit and after 14 days. Results: Mann-Whitney test was used to compare the course of pain during treatment. Pain decrease after two weeks of treatment was significantly higher in group A (PEA) than in group B (NSAID) (p=0.0001); masticatory function improves more in group A than in Group B (p=0.0001). Conclusions: Our preliminary data suggest that PEA is an effective tool for treatment of TMJD, in patients with synovitis and osteoarthritis pain. It is a non-gastrolesive effective analgesic with a longer half-life than NSAID (12 versus 4 hours).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
